Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| BLI850-302 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | multi-dose preparation for oral administration prior to colonoscopy |
|
| 2 | Active Comparator | multi-dose preparation for oral administration prior to colonoscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BLI850 | Drug | multi-dose preparation for oral administration prior to colonoscopy |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy - Preparation Quality Using a 4 Point Scale | Percentage of patients with a successful preparation (cleaning rated as "Good" or "Excellent") | 2 days |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Chemistry Results (mEq/L) | Change from Baseline | 2 days |
| Hematology Results (%) | Change from Baseline | 2 days |
Not provided
Inclusion Criteria:
Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:
At least 18 years of age.
Otherwise in good health, as determined by physical exam and medical history.
If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intra-uterine device, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).
Negative urine pregnancy test at screening, if applicable.
In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Advanced Clinical Research Institute | Anaheim | California | 92801 | United States | ||
| Advanced Clinical Research Institute |
386 subjects were randomized. 15 patients did not take the preparation are were excluded from the Intent-to-treat population.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BLI850 | single administration oral preparation - split dose |
| FG001 | Polyethylene Glycol 3350 Based Bowel Preparation | single administration oral preparation - split dose |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| polyethylene glycol 3350 based bowel preparation |
| Drug |
multi-dose preparation for oral administration prior to colonoscopy |
|
| Serum Chemistry Results (U/L) | Change from Baseline | 2 days |
| Serum Chemistry Results (mg/dL) | Change from Baseline | 2 days |
| Serum Chemistry Results (g/dL) | Change from Baseline | 2 days |
| Serum Chemistry Results - Glomerular Filtration Rate | Change from Baseline | 2 days |
| Hematology Results - Hemoglobin | Change from Baseline | 2 days |
| Hematology Results (1000/MCL) | Change from Baseline | 2 days |
| Hematology Results - Red Blood Cells | Change from Baseline | 2 days |
| Serum Chemistry Results (Osmolality) | Change from Baseline | 2 days |
| Orange |
| California |
| 92869 |
| United States |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | United States |
| Gastrointestinal Associates | Jackson | Mississippi | 39202 | United States |
| Options Health Research | Tulsa | Oklahoma | 74104 | United States |
| Northwest Gastroenterology Clinic | Portland | Oregon | 97210 | United States |
| Franklin Gastroenterology | Franklin | Tennessee | 37067 | United States |
| Memphis Gastroenterology Group | Germantown | Tennessee | 38138 | United States |
| The Frist Clinic | Nashville | Tennessee | 37203 | United States |
| Houston Medical Research Associates | Houston | Texas | 77090 | United States |
| Charlottesville Medical Research | Charlottesville | Virginia | 22911 | United States |
| Northwest Gastroenterology Associates | Bellevue | Washington | 98004 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
Intent-to-treat population
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BLI850 | |
| BG001 | Polyethylene Glycol 3350 Based Bowel Preparation | |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Efficacy - Preparation Quality Using a 4 Point Scale | Percentage of patients with a successful preparation (cleaning rated as "Good" or "Excellent") | 186 patients were included in the BLI850 intent-to-treat population. One patient took the preparation but did not undergo colonoscopy due to insurance coverage issues. This patient is excluded from all efficacy analyses. | Posted | Number | 95% Confidence Interval | percentage of participants | 2 days |
|
|
| ||||||||||||||||||||||||||||
| Secondary | Serum Chemistry Results (mEq/L) | Change from Baseline | Posted | Mean | Standard Deviation | milliequivalent/L | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Hematology Results (%) | Change from Baseline | Intent to treat population | Posted | Mean | Standard Deviation | Percentage of cells | 2 days |
|
| |||||||||||||||||||||||||||||
| Secondary | Serum Chemistry Results (U/L) | Change from Baseline | Posted | Mean | Standard Deviation | U/L | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Serum Chemistry Results (mg/dL) | Change from Baseline | Posted | Mean | Standard Deviation | mg/dL | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Serum Chemistry Results (g/dL) | Change from Baseline | Posted | Mean | Standard Deviation | g/dL | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Serum Chemistry Results - Glomerular Filtration Rate | Change from Baseline | Posted | Mean | Standard Deviation | ml/min | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Hematology Results - Hemoglobin | Change from Baseline | Posted | Mean | Standard Deviation | g/dL | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Hematology Results (1000/MCL) | Change from Baseline | Posted | Mean | Standard Deviation | 1000/MCL | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Hematology Results - Red Blood Cells | Change from Baseline | Posted | Mean | Standard Deviation | million/microliter | 2 days |
|
| ||||||||||||||||||||||||||||||
| Secondary | Serum Chemistry Results (Osmolality) | Change from Baseline | Posted | Mean | Standard Deviation | mOsm/kg | 2 days |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | BLI850 | 1 | 186 | 155 | 186 | |||
| EG001 | Polyethylene Glycol 3350 Based Bowel Preparation | 0 | 185 | 147 | 185 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| abdominal cramping | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal distension | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Overall discomfort | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 360 days from the time submitted to the sponsor for review. The sponsor cannot extent the embargo.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| John McGowan, Director, Clinical Research | Braintree Laboratories, Inc. | 781-843-2202 | jmcgowan@braintreelabs.com |
| ID | Term |
|---|---|
| D003110 | Colonic Neoplasms |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|
|
|
|
|
|
|
|
|
|